A. nAMD has a higher prevalence among men B. nAMD has a similar prevalence among multiple ethnicities C. nAMD has an increased incidence of more than 50% over the last 20 years D. nAMD has a similar incidence between the ages of 65 and 75 E. Unsure

A. Diabetes has a higher prevalence in the Southern US B. DR/DME has a higher prevalence among men C. DR/DME has a similar prevalence among multiple ethnicities D. DR/DME is being effectively diagnosed among the adult population E. Unsure

A. Tralokinumab is FDA approved for DR/DME B. Due to the high treatment burden, anti-VEGF therapy has been ineffective in preventing blindness due to nADM and DR/DME C. Ranibizumab is the only anti-VEGF agent approved for DR/DME D. Treat and Extend (T&E) is a dosing regimen intended to decrease the treatment burden of anti-VEGF injections E. Unsure

A. Gene therapy B. Increasing the molecular size of the anti-VEGF drug to increase vitreous half-life C. Targeting another mechanism of action besides VEGF D. A medical device implanted in the eye for sustained drug release E. Unsure

A. Currently being tested for patients with proliferative diabetic retinopathy (PDR) B. FDA approved for DR/DME C. A long-term drug delivery medical device implanted into the eye D. Associated with vision-threatening complications E. Unsure

A. Laser photocoagulation B. Anti-VEGF injection therapy C. Steroid injection therapy D. Referral to an endocrinologist for better blood glucose control E. Unsure

A. Aflibercept B. Bevacizumab C. Brolucizumab D. Ranibizumab E. Unsure